Aliya Orassay

Ms. Aliya Orassay


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2026 in Brain Sciences
Verified
Journal Article
Open access
PDF file
AGAnastasia Ganina
Anastasia Ganina
NYNaizabek Yerzhigit
Naizabek Yerzhigit
OLOleg Lookin
Oleg Lookin
AOAliya Orassay
Aliya Orassay
GSGaliya Shaimardanova
Galiya Shaimardanova
ABAbay Baigenzhin
Abay Baigenzhin
Background/Objectives: Modern approaches for post-stroke rehabilitation cover mechanistically different ways—from physiotherapy to digital technologies. Among these approaches, stem cell-based therapy represents probably the most complex but promising strategy. Methods: We discuss the current state-of-the-art of using mesenchymal stem cells (MSCs) in post-stroke regenerative therapy. Despite relatively wide use of bone marrow and adipose tissue MSCs, these cells represent a more mature (“adult”) state, which limits their proliferative and regenerative potentials. Compared to the “adult” MSCs, less “mature” MSCs obtained from umbilical cord, specifically Wharton’s jelly MSCs (WJ-MSCs), demonstrate unique functional capabilities and are free from certain technical and ethical issues. Results: The molecular and cellular mechanisms of action of WJ-MSCs are thoroughly discussed in comparison with abundantly used “adult” types of MSCs. We also comparatively evaluate their preclinical and clinical application for treating post-stroke patients. Recent findings indicate that not only MSCs but also their secretome/exosomes (cell-free product) represent a therapeutically beneficial cellular drug in post-stroke recovery. Specially designed and carefully evaluated protocols, which preserve the bioactivity of the cell-free product intact, are mentioned. Neuroprotective and neuroreparative properties of cell-free products—secretome and exosomes—derived from Wharton’s jelly MSCs are summarized. Conclusions: Cell-free products obtained from WJ-MSCs are an innovative adjunct therapy for post-stroke disorders, despite certain challenges and limitations of this type of therapy still present. By further investigation of the molecular composition and biological mechanisms of the WJ-MSC secretome and exosomes, their clinical applicability in neuroinflammatory and neurodegenerative pathologies will be promoted.

13 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RORustam Omarbayev
Rustam Omarbayev
YIYerbol Iskakov
Yerbol Iskakov
AOAliya Orassay
Aliya Orassay
Rinat NugumanovRinat Nugumanov
Rinat Nugumanov
SPSaule Paizullayeva
Saule Paizullayeva
MAManarbek Askarov
Manarbek Askarov
Background/Objectives: Regenerative therapies are increasingly used for organic erectile dysfunction (ED), but their effects on erectile function and clinically meaningful response remain uncertain. We evaluated erectile-function scores, penile hemodynamics, and responder outcomes. Methods: We searched PubMed, Scopus, and Cochrane CENTRAL from January 1999 to June 2026. Controlled, active-comparator, and uncontrolled studies were analysed separately. Random-effects models synthesised continuous and responder outcomes by follow-up period. We assessed risk of bias using RoB 2 and ROBINS-I and rated certainty of evidence using GRADE. Results: We included 46 study reports comprising 18 randomized trials and 28 non-randomized studies. In controlled comparisons, mean International Index of Erectile Function (IIEF) scores favored treatment at short-term follow-up (≤12 weeks; Hedges’ g = 1.08, 95% CI 0.64–1.52). The mid-term estimate was less precise (13–24 weeks; g = 0.49, 95% CI −0.02 to 1.01). Controlled Erection Hardness Score estimates were also imprecise. Risk ratios for study-defined clinically meaningful improvement in the IIEF erectile function domain were 2.51 (95% CI 0.76–8.31), 2.62 (0.56–12.36), and 2.67 (0.58–12.22) at 4, 12, and 24 weeks, respectively. Exploratory within-group analyses showed post-treatment changes in erectile function and peak systolic velocity, with substantial heterogeneity across several analyses. Conclusions: Controlled studies favored regenerative therapies for short-term improvement in mean erectile-function scores. Whether more patients achieve a clinically meaningful response, how long any benefit lasts, and which therapies are most effective remain uncertain. The review was registered with PROSPERO (CRD420261421415).